The FDA is reconsidering the black box warning on estrogen. Experts say it’s time for a change—find out what this means for ...

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

Hone Health reports that the controversial 2002 WHI study misled menopause care, linking HRT to breast cancer and causing ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

FDA Commissioner Marty Makary, MD, MPH, announced that George Tidmarsh, MD, PhD, a cancer and pediatric specialist, will ...

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate cancer.

JUUL GETS ITS CROWN — The FDA authorized Juul’s applications on Thursday to sell e-cigarettes in the U.S., determining ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

The FDA has granted priority review to an application for Revuforj for the treatment of relapsed or refractory mutant NPM1 acute myeloid leukemia.

Combination therapy screening is the process of testing multiple drugs together to see how they interact. The goal is to find ...